|
Patent landscape, scope, and claims: |
United States RE39706 (Calcipotriol Monohydrate) — Claim Scope and US Patent Landscape
What is RE39706 and what claims define the US protected subject matter?
US RE39706 is a US reissue patent that narrows the protected subject matter to (i) calcipotriol in a specific solid-state form (monohydrate) and (ii) that solid-state form’s performance-defined attributes, plus (iii) formulations and processing steps that use the specified hydrate.
From the claim set provided, the scope clusters into three layers:
- Product-by-characterization: calcipotriol monohydrate with defined storage stability at 40°C for 12 months, ready wettability, and suitability for wet ball milling.
- Composition claims: pharmaceutical compositions (cream/gel/ointment/lotion/solution/suspension) containing the claimed monohydrate at 1–100 μg/g.
- Process and unit-operation claims: preparation of the hydrate via dissolving calcipotriol in an organic solvent then adding water to precipitate hydrate, and wet ball milling-based gel preparation using the hydrate as the milled starting component.
- Analytical identity support: optional dependent claim limitations requiring IR and solid-state CPMAS 13C NMR spectral lines/resonances.
What exactly do the claims cover (claim-by-claim scope map)?
Below is a structured scope map keyed to your claim list.
A. Solid-state active ingredient claims (core of protection)
Claim 1 (independent):
- Covers calcipotriol monohydrate characterized by:
- Storage stability: stable at 40°C after 12 months
- Ready wettability
- Suitability for wet ball milling (i.e., the hydrate performs in wet milling conditions)
Claims 8–9 (dependent, analytical identity):
- Claim 8: Claim 1 hydrate has a specific IR spectrum (KBr technique) with characteristic lines:
1455 (m), 1442 (m), 1330 (w), 1290 (m), 1210 (m), 1085 (m), 907 (m), 895 (m), 573 (w) cm−1
- Claim 9: Claim 1 hydrate has a specific solid state CPMAS 13C NMR set of resonances:
147.9, 146.5, 134.8, 130.3, 129.0, 126.5, 116.0, 109.4, 75.5, 68.2, 67.2, 56.9, 55.2, 47.8, 47.5, 42.9, 42.0, 41.3, 30.7, 28.9, 25.6, 23.1, 22.6, 19.5, 14.6, 6.2, 1.9 ppm
Practical scope implication: Claim 1 is the dominant capture claim. Claims 8–9 add enforceable identity constraints on a subset of embodiments (which still depend on meeting the performance-defined hydrate properties).
B. Formulation claims (use of the protected monohydrate in dosage forms)
Claim 2 (independent composition platform):
- A pharmaceutical composition containing the compound of Claim 1 (calcipotriol monohydrate with the performance characteristics).
From there, the claim set staggers into multiple dosage-form-specific dependent claims and then broadens to composition claims that include quantitative active loading.
Dosage form dependent claims:
- Claim 3: cream
- Claim 4: gel
- Claim 12: ointment
- Claim 13: lotion
- Claim 14: solution
- Claim 15: suspension
Analytical dependent claims on the composition:
- Claim 10: composition has the specific IR lines (same as Claim 8).
- Claim 11: composition has the specific CPMAS 13C NMR resonances (same as Claim 9).
Loading-defined dependent claims:
- Claim 5: composition in the framework of Claims 2–4 (i.e., cream/gel depending on interpretation of “claim 4 claims 2-4”) comprising:
- calcipotriol monohydrate as defined, plus pharmaceutically acceptable vehicle
- active content 1–100 μg/g
- Claim 16: ointment + vehicle, active 1–100 μg/g
- Claim 17: lotion + vehicle, active 1–100 μg/g
- Claim 18: solution + vehicle, active 1–100 μg/g
- Claim 19: suspension + vehicle, active 1–100 μg/g
Practical scope implication: The formulation claims are enforceable only when the incorporated active matches the Claim 1 hydrate definition, not merely “calcipotriol” generically. If an accused product uses a different solid form (other hydrate, solvates, amorphous, different particle engineering without meeting the hydrate characterization), the composition claims are structurally harder to map.
C. Method/process claims (how the hydrate and the hydrate-enabled gel are made)
Claim 6 (independent process):
- Method comprises:
- dissolve calcipotriol in an organic solvent
- add water to the resulting solution to precipitate the hydrate
- The precipitated hydrate is defined by:
- storage stability at 40°C after 12 months
- ready wettability
- suitability for wet ball milling
Claim 7 (independent method for gel manufacturing using the hydrate):
- In preparation of a gel formulation involving:
- wet ball milling a calcipotriol component
- adding the wet milled calcipotriol component to a gel base
- The improvement comprises:
- wet milling calcipotriol hydrate as the milled component
- using this wet milled hydrate for addition to the gel base
- The hydrate is characterized by the same performance criteria:
- storage stability at 40°C after 12 months
- ready wettability
- suitability for wet ball milling
Practical scope implication: Claim 7 targets a specific unit operation choice (wet ball milling the hydrate rather than other forms) and then downstream gel manufacture. Claim 6 targets the hydrate crystallization route (organic dissolution plus water addition precipitation).
How do dependent analytical claims shift enforcement leverage?
Claims 8–9 and 10–11 convert a performance-defined hydrate into an evidence-supported identity definition.
- For infringement strategy by a patentee: analytical claims give concrete test endpoints (IR line list and CPMAS 13C NMR resonance list). Even if accused products argue performance differences, the spectral match is a strong evidentiary anchor.
- For infringement risk in practice: if a manufacturer can show its solid form does not match the claimed spectra, the patentee still has to rely primarily on the performance-defined Claim 1 characteristics. Conversely, if spectra match, defendants face a narrower route: they must prove lack of one or more Claim 1 performance characteristics (storage stability, wettability, milling suitability), or show the hydrate is not truly the claimed monohydrate.
What is the scope boundary between “calcipotriol hydrate” and “calcipotriol monohydrate”?
From the claim text:
- The product scope is explicitly “calcipotriol monohydrate”.
- Claims repeatedly require the hydrate to be characterized by the 40°C stability, wettability, and wet ball milling suitability.
That means the intellectual property focus is not merely “a hydrate” but a specific stoichiometric hydrate form plus performance criteria. The analytical claim language further ties identity to monohydrate structure by IR and CPMAS 13C NMR features.
United States patent landscape: where RE39706 sits (and what it likely blocks)
What does RE39706 most likely cover in the US lifecycle of calcipotriol products?
Based on the claim set structure, RE39706 is best viewed as covering:
-
Active ingredient solid-form substitution risk
- Competitors using other solid forms may avoid Claim 1/2/3/4-type scope.
- Competitors using the same monohydrate (including through processes achieving the same stability/wettability/milling characteristics) risk direct infringement across product and formulation claims.
-
Manufacturing process substitution risk
- Claim 6 can be asserted against suppliers or manufacturers whose crystallization step is “dissolve in organic solvent then add water to precipitate hydrate” where the resulting hydrate meets the performance definitions.
- Claim 7 can be asserted against gel manufacturers who wet ball mill a calcipotriol component where the milled component is the claimed hydrate and is then used in gel manufacture.
-
Formulation substitution risk
- Dosage forms listed cover several common dermal presentations: cream, gel, ointment, lotion, solution, suspension.
- If the formulation uses the claimed hydrate at 1–100 μg/g, loading claims are directly implicated for those dosage forms where the claim language includes the explicit range.
What is the “center of gravity” for freedom-to-operate design?
A practical enforcement center of gravity is:
- Whether an at-risk product’s active ingredient is the calcipotriol monohydrate characterized by:
- 40°C stability after 12 months
- ready wettability
- wet ball milling suitability
Everything else is derivative:
- Formulations depend on incorporation of that active.
- Process claims depend on producing and using that hydrate.
Claim coverage matrix for US competitive products
The following matrix maps claim dependencies to typical competitive substitutions.
| Competitive change |
Likely impact on RE39706 risk |
Relevant claim hooks |
| Switch from calcipotriol monohydrate to another hydrate/solvate/amorphous form |
Reduces risk if not meeting Claim 1 hydrate definition |
Claims 1, 2 (depends on Claim 1 compound) |
| Keep same solid form but change crystallization route |
Could avoid Claim 6 if resulting hydrate not made by the claimed route |
Claim 6 |
| Keep solid form but avoid wet ball milling hydrate in gel process |
Reduces risk against gel-manufacturing method |
Claim 7 |
| Keep method but change dosage form (e.g., tablet) |
Not covered by listed topical dosage forms |
Claims 3–4, 12–15 |
| Use the hydrate but vary active loading out of 1–100 μg/g |
Can reduce exposure to loading-defined dependents |
Claims 5, 16–19 |
| Use the hydrate but demonstrate non-matching IR/NMR identity |
Shifts dispute from performance to identity evidence |
Claims 8–9, 10–11 |
Key takeaways
- RE39706’s enforceable core is a specific solid form: calcipotriol monohydrate defined by 40°C stability for 12 months, ready wettability, and wet ball milling suitability (Claim 1).
- Product coverage is derivative: creams, gels, ointments, lotions, solutions, and suspensions are implicated when they contain the Claim 1 monohydrate (Claims 2–4, 12–15).
- Dosage-form risk is enhanced by loading limits in select dependents: 1–100 μg/g (Claims 5, 16–19).
- Process claims expand enforcement beyond final products: crystallization by organic dissolution then water precipitation (Claim 6) and gel manufacture using wet-ball-milled hydrate as the milled component (Claim 7).
- Analytical dependent claims (IR line list and solid-state CPMAS 13C NMR resonance list) provide concrete test criteria that can be used to tie an accused material to the claimed monohydrate identity (Claims 8–9, 10–11).
FAQs
-
Does RE39706 protect calcipotriol regardless of solid form?
No. The claims require calcipotriol monohydrate characterized by specified storage stability at 40°C after 12 months, ready wettability, and wet ball milling suitability (Claim 1).
-
Which formulation types are within claim coverage?
The claim set includes cream, gel, ointment, lotion, solution, and suspension (Claims 3–4, 12–15), each built around incorporating the Claim 1 monohydrate.
-
Is active loading constrained across all formulation claims?
Loading is expressly limited to 1–100 μg/g in specific dependents (Claims 5, 16–19). Other formulation dependents rely on incorporation of Claim 1 without stating the same range.
-
What are the enforceable process steps?
Two main process themes: precipitating the hydrate by dissolve in organic solvent then add water to precipitate (Claim 6), and preparing gels by wet ball milling the hydrate and adding the milled hydrate to the gel base (Claim 7).
-
How do IR and CPMAS 13C NMR claims affect infringement proof?
The analytical claims provide explicit spectral identity anchors tied to the Claim 1 hydrate, using defined IR characteristic lines (Claims 8, 10) and CPMAS 13C NMR resonances (Claims 9, 11).
References
[1] United States Reissue Patent No. RE39706 (calcipotriol monohydrate; storage stability at 40°C after 12 months; IR and solid-state CPMAS 13C NMR characterization; formulation and preparation methods).
More… ↓
⤷ Start Trial
|
